1. What Is the Designer Phage Market?
The Designer Phage Market covers engineered bacteriophage products targeting and killing specific bacterial pathogens for therapeutic, agricultural, and biocontrol application including phage cocktail therapy for antibiotic-resistant infection. Designer phage encompasses antimicrobial phage therapy, engineered phage with expanded host range, phage biocontrol for crop disease, phage biosensor, and phage-antibiotic combination product. Market dynamics reflect antimicrobial resistance creating unmet clinical need, FDA expanded access enabling compassionate use phage therapy, and synthetic biology enabling phage genome engineering at speed.
2. Designer Phage Market Size & Forecast
3. Emerging Technologies
- Synthetic phage genome enabling de novo design with programmable host range are advancing. Growing investment is driven by natural phage host range extension to cover resistant pathogen.
- Phage-antibiotic combination achieving bacterial kill at sub-inhibitory antibiotic dose are advancing. Growing investment is driven by antibiotic dose reduction in combination therapy.
- Phage endolysin achieving biofilm disruption on implant and wound surface are advancing. Growing clinical and biotechnology organisation investment is driven by biofilm-associated implanted device infection treatment requirements that antimicrobial resistance renders increasingly difficult to address through conventional antibiotic therapy.
- Encapsulated phage enabling oral delivery with gastric acid protection for gut pathogen are advancing. Growing development is driven by gut microbiome targeted infection therapy route.
Similar technologies are also transforming adjacent markets. Learn more in our Early Toxicity Testing Market.
4. Key Market Opportunity
The leading opportunity in the Designer Phage Market is the compassionate use and clinical phage therapy, where Adaptive demonstrates personalised phage for AMR infection. Agricultural biocontrol creates a commercial opportunity as Intralytix achieves food safety market entry. Phage endolysin creates a drug-like opportunity with antibiotic-like development pathway. Asia Pacific creates expansion as Chinese, South Korean, and Georgian clinical phage programme grows.
5. Top Companies in the Designer Phage Market
The following organisations hold leading positions in the Designer Phage Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Adaptive Phage Therapeutics
- Armata Pharmaceuticals
- Phagobiotics (Poland)
- Intralytix (ListShield)
- Micreos (StaphEffekt)
- BiomX
- Locus Biosciences
- Pherecydes Pharma (France)
- Eliava Institute (Georgia)
- UC San Diego Phage Therapy Center
6. Market Segmentation
The Designer Phage Market is analysed across 3 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Application | Phage Therapy AMR Infection Agricultural Biocontrol Food Safety Phage Phage Biosensor Biofilm Disruption |
| By Type | Natural Phage Cocktail Engineered Phage Phage Endolysin Phage-Antibiotic Combination |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Designer Phage Market trajectory over the forecast period:
Adaptive Phage Therapeutics and Phagobiotics Achieve Clinical Phage Therapy Market Entry.Adaptive Phage Therapeutics and Phagobiotics achieving combined 50 compassionate use phage therapy patients in 2024 demonstrate clinical phage at regulatory access pathway scale. Adaptive achieving FDA expanded access approval for personalised phage demonstrates the pathway enabling clinical use.
Armata Pharmaceuticals Achieves Phase 2 Phage Therapy Trial for CRPA Lung Infection.Armata AP-PA02 achieving Phase 2 enrolment for chronic P. aeruginosa lung infection in 2024 demonstrates clinical phage at randomised controlled trial milestone. Armata achieving primary endpoint lung function improvement signal demonstrates the clinical benefit hypothesis.
Intralytix and Micreos Achieve Commercial Phage Biocontrol and Food Safety Market Entry.Intralytix ListShield and Micreos StaphEffekt achieving combined 100 commercial food safety and agricultural phage product deployments in 2024 demonstrate phage biocontrol at commercial market entry. ListShield achieving FDA GRAS status for Listeria biocontrol demonstrates the regulatory approval enabling commercial use.
For related market intelligence, see the Regenerative Medicine Market.
8. Segmental Analysis
By type, the Natural Phage Cocktail Therapy segment dominated in 2025 as the most deployed category as compassionate use cocktail drives clinical adoption. The Engineered Phage segment is the fastest-growing category, advancing as synthetic biology enables programmable host range.
By application, AMR Phage Therapy dominated in 2025, while Agricultural Biocontrol is registering the highest commercial growth rate.
9. Regional Analysis
Regional demand patterns across the Designer Phage Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America accounted for the largest share of the Designer Phage Market in 2025, holding 53.8% of the global market. Biotechnology companies, phage biology research institutions, and clinical antimicrobial resistance programmes are advancing designer phage development for precision antimicrobial therapy, engineered microbiome modulation, and therapeutic synthetic biology applications. FDA compassionate use engagement with designer phage therapies and growing NIH antimicrobial resistance research investment are encouraging designer phage development. Strong biotechnology research ecosystem, established synthetic biology capability, and growing clinical interest in phage-based antimicrobial alternatives are generating regional development activity.
Highest CAGR Region
Europe is expected to register the highest CAGR of 33.09% during the forecast period. European biotechnology companies, clinical phage therapy programmes, and academic microbiology organisations across Belgium, Germany, France, Georgia, and Switzerland are advancing designer phage development for antimicrobial resistance treatment and precision microbiome applications. EMA regulatory engagement with advanced phage therapy and growing European research investment in bacteriophage engineering are encouraging development. Rising antimicrobial resistance urgency in European healthcare and strong academic-industry research partnerships are generating European designer phage development.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Designer Phage Market was valued at USD 478.00 Mn in 2025 and is projected to reach USD 4,630.60 Mn by 2034, growing at a CAGR of 28.7% over the 2026–2034 forecast period.
The Designer Phage Market is projected to grow at a CAGR of 28.7% from 2026 to 2034.
North America accounted for the largest share of the Designer Phage Market in 2025, holding 53.8% of the global market.
The leading companies in the Designer Phage Market include Adaptive Phage Therapeutics, Armata Pharmaceuticals, Phagobiotics (Poland), Intralytix (ListShield), Micreos (StaphEffekt), BiomX, Locus Biosciences, Pherecydes Pharma (France), Eliava Institute (Georgia), UC San Diego Phage Therapy Center.
Adaptive phage therapeutics and phagobiotics achieve clinical phage therapy market entry.
By type, the Natural Phage Cocktail Therapy segment dominated in 2025 as the most deployed category as compassionate use cocktail drives clinical adoption.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.